<DOC>
	<DOCNO>NCT01664026</DOCNO>
	<brief_summary>To evaluate effect 6-month web-based lifestyle modification program without telephone counsel versus usual care obese patient cardiovascular risk factor : - Weight Loss - Waist circumference ; blood pressure ; total cholesterol , triglyceride , LDL-cholesterol , HDL-cholesterol ; glucose hemoglobin A1c ; C-reactive protein . - Physical activity eat habit - Quality life</brief_summary>
	<brief_title>Efficacy Web-based Lifestyle Modification Program Obese Patients With Cardiovascular Risk Factors</brief_title>
	<detailed_description />
	<criteria>1 . Male female 2570 year age 2 . Obese ( BMI ≥ 30 kg/m2 &lt; 40 kg/m2 ) 3 . At least 2 cardiovascular risk factor ( diabetes , hypertension dyslipidemia ) ) Hypertension define history hypertension , treatment hypertension BP value &gt; 140/90 mmHg two consecutive office visit ii ) High cholesterol define LDLC ≥130 mg/dL and/or HDLC &lt; 40 mg/dL triglyceride ≥150 mg/dL iii ) Type 2 Diabetes Mellitus define history diabetes , treatment diabetes fast glucose ≥126 mg/dL two consecutive office visit 4 . Participant must willing able provide write informed consent 5 . Participant must willing able comply study relate procedure 6 . Participant must access Internet email 1 . Stage 1 2 Patient Activation Measures tool 2 . Weight change 5 kg 3 month precede screen visit 3 . History bariatric surgery 4 . Fasting Plasma Glucose screen &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) 5 . Hemoglobin A1c screen &gt; 8.5 % 6 . Treatment type 2 diabetes insulin ( except history intermittent acute use , 2 week usage previous 6 month ) 7 . Uncontrolled inadequately control hypertension time screen blood pressure &gt; 160/100 mmHg 8 . Secondary hypertension 9 . Changes lipid , blood pressure diabetes modify agent include introduction , change dose cessation 3 month prior Screening Visit 10 . Personal history coronary heart disease , congestive heart failure , serious arrhythmia stroke 11 . Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease make implementation protocol interpretation study result difficult . 12 . Presence condition ( medical , psychological , social , geographical ) , actual anticipate , opinion Investigator would restrict limit patient 's successful participation duration study 13 . Presence history cancer within past five year exception adequately treat localized basal cell skin cancer situ uterine cervical cancer 14 . Use systemic glucocorticoid ( exclude topical application inhale form ) one week within 3 month prior time screen 15 . Use investigational agent ( drug , biologic , device ) within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>